Last reviewed · How we verify
GSK1120212 plus everolimus
At a glance
| Generic name | GSK1120212 plus everolimus |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) (PHASE1)
- Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (PHASE1)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (PHASE2)
- GSK1120212 Rollover Study (PHASE2)
- A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1120212 plus everolimus CI brief — competitive landscape report
- GSK1120212 plus everolimus updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI